Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

A molecular taxonomy for urothelial carcinoma.

Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, Månsson W, Liedberg F, Lindgren D, Höglund M.

Clin Cancer Res. 2012 Jun 15;18(12):3377-86. doi: 10.1158/1078-0432.CCR-12-0077-T. Epub 2012 May 2.

2.

Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

Lindgren D, Frigyesi A, Gudjonsson S, Sjödahl G, Hallden C, Chebil G, Veerla S, Ryden T, Månsson W, Liedberg F, Höglund M.

Cancer Res. 2010 May 1;70(9):3463-72. doi: 10.1158/0008-5472.CAN-09-4213. Epub 2010 Apr 20.

3.

Bladder cancer: translating molecular genetic insights into clinical practice.

Cheng L, Zhang S, MacLennan GT, Williamson SR, Lopez-Beltran A, Montironi R.

Hum Pathol. 2011 Apr;42(4):455-81. doi: 10.1016/j.humpath.2010.07.007. Epub 2010 Nov 24. Review.

PMID:
21106220
4.

Toward a molecular pathologic classification of urothelial carcinoma.

Sjödahl G, Lövgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, Aine M, Eriksson P, Månsson W, Lindgren D, Fernö M, Liedberg F, Höglund M.

Am J Pathol. 2013 Sep;183(3):681-91. doi: 10.1016/j.ajpath.2013.05.013. Epub 2013 Jul 1.

5.

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.

van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boevé ER, Jöbsis AC, Zwarthoff EC.

J Clin Oncol. 2003 May 15;21(10):1912-21.

PMID:
12743143
6.

A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.

Patschan O, Sjödahl G, Chebil G, Lövgren K, Lauss M, Gudjonsson S, Kollberg P, Eriksson P, Aine M, Månsson W, Fernö M, Liedberg F, Höglund M.

Eur Urol. 2015 Nov;68(5):824-32; discussion 835-6. doi: 10.1016/j.eururo.2015.02.021. Epub 2015 Mar 11.

PMID:
25770486
7.

Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes.

Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, Cordon-Cardo C.

Cancer Res. 2002 Dec 1;62(23):6973-80.

8.

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S.

Hum Pathol. 2012 Oct;43(10):1573-82. doi: 10.1016/j.humpath.2011.10.026. Epub 2012 Mar 12.

PMID:
22417847
9.

FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.

Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK, de Medina SG.

Cancer Res. 2003 Dec 1;63(23):8108-12.

10.

Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.

Eriksson P, Aine M, Veerla S, Liedberg F, Sjödahl G, Höglund M.

BMC Med Genomics. 2015 May 26;8:25. doi: 10.1186/s12920-015-0101-5.

13.

Genetic and molecular markers of urothelial premalignancy and malignancy.

Cordon-Cardo C, Cote RJ, Sauter G.

Scand J Urol Nephrol Suppl. 2000;(205):82-93. Review.

PMID:
11144907
14.

Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series.

Raspollini MR, Sardi I, Giunti L, Di Lollo S, Baroni G, Stomaci N, Menghetti I, Franchi A.

Hum Pathol. 2011 Aug;42(8):1149-58. doi: 10.1016/j.humpath.2010.11.011. Epub 2011 Feb 21.

PMID:
21334719
15.

[Histopathology of urothelial carcinomas: crucial for patient management].

Lindemann-Docter K, Knüchel-Clarke R.

Urologe A. 2008 May;47(5):627-36; quiz 637. doi: 10.1007/s00120-008-1736-z. German.

PMID:
18427766
16.

Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis.

Lopez-Beltran A, Amin MB, Oliveira PS, Montironi R, Algaba F, McKenney JK, de Torres I, Mazerolles C, Wang M, Cheng L.

Am J Surg Pathol. 2010 Mar;34(3):371-6. doi: 10.1097/PAS.0b013e3181cd385b.

PMID:
20139762
17.

FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.

van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, Hofstaedter F, Steyerberg EW, Klinkhammer-Schalke M, Zwarthoff EC, van der Kwast TH, Hartmann A.

Eur Urol. 2007 Sep;52(3):760-8. Epub 2007 Jan 12.

PMID:
17240035
18.

Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles.

Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, Bojar H, Vögeli TA, Grimm MO.

Clin Cancer Res. 2004 May 15;10(10):3410-21.

19.

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE.

J Natl Cancer Inst. 1993 Jan 6;85(1):53-9.

PMID:
7677935
20.

Frequent FGFR3 mutations in urothelial papilloma.

van Rhijn BW, Montironi R, Zwarthoff EC, Jöbsis AC, van der Kwast TH.

J Pathol. 2002 Oct;198(2):245-51.

PMID:
12237885

Supplemental Content

Support Center